Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics noninvasively.
Detection of ctDNA can be challenging in patients with low-volume or residual disease, …

Glioma‐derived cell‐free DNA (cfDNA) is challenging to detect using liquid biopsy because
quantities in body fluids are low. We determined the glioma‐derived DNA fraction in …

Background High-throughput sequencing of cell-free DNA fragments found in human plasma
has been used to non-invasively detect fetal aneuploidy, monitor organ transplants and …

Glioma is difficult to detect or characterize using current liquid biopsy approaches. Detection
of cell‐free tumor DNA (cft DNA ) in cerebrospinal fluid ( CSF ) has been proposed as an …

Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode
of 166 bp. Data supporting this view has been mainly acquired through the analysis of …

Background Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of
cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a …

Circulating tumor DNA (ctDNA) offers new opportunities for noninvasive cancer management.
Detecting ctDNA in plasma is challenging because it constitutes only a minor fraction of …

These findings show that detection of tumor mitochondrial DNA is more sensitive than
circulating tumor DNA analysis to detect and monitor tumor burden in patient-derived orthotopic …

Tumour heterogeneity leads to the development of multiple resistance mechanisms during
targeted therapies. Identifying the dominant driver(s) is critical for treatment decision. We …